Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?

International audience

A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus

International audience

Influence of magnesium on biochemical parameters of iron and oxidative stress in patients with type 2 diabetes

Introduction: Studies have shown that oxidative stress, found in patients with type 2 diabetes, may be due to changes in the metabolism of minerals, such as magnesium and iron. Data related to compartmentalization of these minerals in diabetes are scarce and controversial. Objective: This study assessed the influence of magnesium on biochemical parameters of iron and oxidative stress in patients with type 2 diabetes. Methods: A case-control study in male and female subjects aged 27-59 years, divided into two groups: type 2 diabetes (n=40) and control (n=48). Intake of magnesium and iron was assessed by three-day food record. Plasma, erythrocyte and urinary levels of magnesium, serum iron, ferritin, total iron binding capacity, fasting glucose, glycated hemoglobin, insulin, creatinine clearance and plasma thiobarbituric acid reactive substances (TBARS) were analyzed. Results and Discussion: Magnesium intake and plasma magnesium were lower in diabetic subjects. There was low urinary magnesium excretion, with no difference between groups. Although normal, the diabetic group had lower serum iron and ferritin concentrations compared to control subjects. Plasma TBARS in diabetic patients was higher than control while creatinine clearance was lower. An inverse correlation between erythrocyte magnesium and serum iron and ferritin was observed in the diabetes group. Conclusions: Diabetes induced hypomagnesemia and this, associated with chronic hyperglycemia, may have enhanced oxidative stress. Erythrocyte magnesium may have contributed to prevent iron overload and worsening of oxidative stress and hyperglycemic status.

Association between ferritin, high sensitivity c-reactive protein (hsCRP) and relative abundance of Hepcidin mRNA with the risk of type 2 diabetes in obese subjects

Obesity and Type 2 diabetes mellitus share a strong pro-inflammatory profile. It has been observed that iron is a risk factor in the development of type 2 diabetes. The aim of this study was to evaluate the relationship between iron nutritional status and inflammation with the risk of type 2 diabetes development in obese subjects. We studied 30 obese men with type 2 diabetes (OBDM); 30 obese subjects without diabetes (OB) and 30 healthy subjects (Cn). We isolated peripheral mononuclear cells (PMCs) and challenged them with high Fe concentrations. Total mRNA was isolated and relative abundance of TNF-αIL-6 and hepcidin were determined by qPCR. Iron status, biochemical, inflammatory and oxidative stress parameters were also characterized. OBDM and OB patients showed increased hsCRP levels compared to the Cn group. OBDM subjects showed higher levels of ferritin than the Cn group. TNF-α and IL-6 mRNA relative abundances were increased in OBDM PMCs treated with high/Fe. Hepcidin mRNA was increased with basal and high iron concentration. We found that the highest quartile of ferritin was associated with an increased risk of type 2 diabetes when it was adjusted to BMI and HOMA-IR; this association was independent of the inflammatory status. The highest level of hepcidin gene expression also showed a trend of increased risk of diabetes, however it was not significant. Levels of hsCRP over 2 mg/L showed a significant trend of increasing the risk of diabetes. In conclusion, iron may stimulate the expression of pro-inflammatory genes (TNF-α and IL-6), and both hepcidin and ferritin gene expression levels could be a risk factor for the development of type 2 diabetes. Subjects that have an increased cardiovascular risk also have a major risk to develop type 2 diabetes, which is independent of the BMI and insulin resistance state.

Chromium supplementation in patients with type 2 diabetes and high risk of type 2 diabetes: a meta-analysis of randomized controlled trials

Introduction: Chromium is an essential trace mineral for carbohydrate and lipid metabolism, which is currently prescribed to control diabetes mellitus. Results of previous systematic reviews and meta-analyses of chromium supplementation and metabolic profiles in diabetes have been inconsistent. Aim: The objective of this meta-analysis was to assess the effects on metabolic profiles and safety of chromium supplementation in type 2 diabetes mellitus and cholesterol. Methods: Literature searches in PubMed, Scopus and Web of Science were made by use of related terms-keywords and randomized clinical trials during the period of 2000-2014. Results: Thirteen trials fulfilled the inclusion criteria and were included in this systematic review. Total doses of Cr supplementation and brewer's yeast ranged from 42 to 1,000 µg/day, and duration of supplementation ranged from 30 to 120 days. The analysis indicated that there was a significant effect of chromium supplementation in diabetics on fasting plasma glucose with a weighted average effect size of -29.26 mg/dL, p = 0.01, CI 95% = -52.4 to -6.09; and on total cholesterol with a weighted average effect size of -6.7 mg/dL, p = 0.01, CI 95% = -11.88 to -1.53. Conclusions: The available evidence suggests favourable effects of chromium supplementation on glycaemic control in patients with diabetes. Chromium supplementation may additionally improve total cholesterol levels.

Relação entre o score de adesão à dieta mediterrânica e a hemoglobina glicosilada em pessoas com diabetes mellitus tipo 2

Poster apresentado no XIV Congresso de Nutrição e Alimentação. Centro de Congressos de Lisboa, 21-22 Maio de 2015

Prevalencia de la hipertensión arterial esencial y factores relacionados en personas con diabetes mellitus tipo 2. Fundación DONUM-2006

Se realizó un estudio transversal en un universo de 406 pacientes. La muestra se calculó al azar, sobre la base de una prevalencia de hipertensión arterial en diabéticos del 53 por ciento, nivel de confianza 95 por ciento y error de inferencia 5 por ciento. Los datos fueron obtenidos de las historias clínicas y analizados con la ayuda del software Epi-Info. La muestra, 200 pacientes, estaba representadapor 74.5 por ciento de sexo femenino, 93.0 por cientocon instruccion primaria y 67.5 por ciento con edad inferior a 65 años. La prevalencia de hipertensión arterial fue del 52.5 por ciento, con un intervalo al 95 por ciento de confianza entre el 45.6 y 59.4 por ciento (IC 95 por ciento). La asociacion entr hipertensión arterial con hipercolesterolemia proporcionó un p=0.20, razón de prevalencia (PR) de 1.20 (IC 95 por ciento 0.90 - 1.60); con hipertrigliceridemia p=0.35, PR 0.87 (IC 95 por ciento 0.66-1.50; con dislipidemia mixta p=0.67, PR 1.06 (IC 95 por ciento 0.81-1.38) y con el sobrepeso p=0.10, PR 1.39 (IC 95 por ciento 0.89 - 2.17. La prevalencia de hipertensión arterial esencial en pacientes con diabetes mellitus tipo 2 fue del 52.5 por ciento (IC 95 por ciento 45.6 - 59.4 por ciento). No se encontró asociación significativa entre pacientes con hipertensión arterial esencial y diabetes mellitus tipo 2 con dislipidemia y sobrepeso

Conocimientos, actitudes y prácticas en pacientes con diabetes mellitus tipo 2 que acuden al centro de atención ambulatoria 302 del IESS en el periodo de mayo a julio, Cuenca Ecuador, 2015

Objetivo Determinar el nivel de conocimientos, actitudes y prácticas en pacientes con Diabetes mellitus tipo 2 que acudieron al centro de Atención Ambulatorio 302 del Instituto Ecuatoriano de Seguridad Social, de la ciudad de Cuenca, durante mayo a julio de 2015. Material y métodos Se realizó un estudio descriptivo, en una muestra no probabilística de 289 pacientes durante el periodo de mayo a julio de 2015. Los datos de conocimientos, actitudes y prácticas se obtuvieron por entrevista directa mediante la aplicación de cuestionarios validados y fueron analizados con el software SPSS versión 2015. Resultados La edad osciló entre 40 y 94 años, con una mediana de 69. El 61,6% fueron mujeres. El 91% residía en el área urbana. La mediana del tiempo de evolución de la diabetes fue 12 años. El nivel de conocimientos adecuados en diabetes fue 1,4%; intermedio de 61% e inadecuado de 77,5%. Actitudes positivas se detectó en el 88,2%, neutra 6,6% y negativas 5,2%. Muy buenas prácticas se determinaron en 5.5%, buenas prácticas en 67.1%, y malas prácticas en 27.3%. Conclusión La aplicación de los cuestionarios nos permitió determinar cuáles son las falencias de los diabéticos; para que tanto médicos como personal de salubridad, diseñen y apliquen estrategias, métodos de aprendizaje y comunicación para aumentar el nivel de conocimientos y prácticas, en pro de disminuir las tasas de morbimortalidad a causa de esta patología.

Factors associated with hypoglycemia episodes in hospitalized type 2 diabetes mellitus patients in a tertiary health facility in Malaysia

Purpose: To determine the factors associated with severity of hypoglycemia in hospitalized type 2 diabetes mellitus patients in a tertiary health facility in Malaysia. Methods: This retrospective study involved 207 hospitalised T2DM patients with hypoglycaemia episodes from January 2008 to December 2012 and was conducted in University Malaya Medical Centre, Petaling Jaya, Malaysia. Patients were classified into 2 groups, viz, those who had hypoglycaemia on admission and those who had hypoglycaemia during hospital stay. Patients with hypoglycemia on admission were those admitted due to hypoglycemia while patients with hypoglycemia during hospital stay were those admitted due to other causes but subsequently developed hypoglycemia during hospitalization. Results: The results for the 207 patients investigated show that most of the patients (72.2 %) were asymptomatic during hypoglycemic episodes. The majority of the episodes (57.4 %) experienced by the patients were mild hypoglycemia (< 3.9 mmol/L). Old age (p = 0.011) and presence of stroke (p = 0.033) were found to be significantly associated with severe hypoglycemia (< 2.2 mmol/L) while concurrent use of opioid (p = 0.008) was associated with mild hypoglycemia. Conclusion: The identification of the underlying factors associated with severity of hypoglycemia may help in preventing and resolving hypoglycemia in T2DM patients.

Prevalencia de no adherencia a la terapia con insulina y factores sociales asociados en pacientes con diabetes mellitus tipo 2 de la consulta externa de endocrinología del Hospital Vicente Corral Moscoso”, de la ciudad de Cuenca.2015

ANTECEDENTES: De acuerdo al estudio CODE-2 (Costo de la Diabetes en Europa: tipo 2) halló que en Europa solo el 28% de los pacientes diabéticos logra un buen control glucémico. En Ecuador durante el año 2011, se registraron 4.455 muertes a causa de Diabetes Mellitus, convirtiéndose en la principal causa de mortalidad general con un porcentaje de 7,15% (INEC). OBJETIVO GENERAL: Determinar la prevalencia de no adherencia al tratamiento con insulina y factores sociales asociados al mismo, en pacientes con Diabetes Mellitus tipo 2, en la consulta externa de endocrinología del “Hospital Vicente Corral Moscoso” en la ciudad de Cuenca 2015. METODOLOGÍA: Se realizó un estudio cuantitativo analítico transversal con una muestra de 225 pacientes insulino-requirentes de la consulta externa de endocrinología del Hospital Vicente Corral Moscoso. Se trabajó con el porcentaje de incidencia de la ALAD para insulino requerimiento (55%) se calculó 225 pacientes a quienes se sometieron a una encuesta para determinar la no adherencia. Los datos obtenidos fueron tabulados y analizados en el programa SPSS. USO DE RESULTADOS: Como fuente de información, para estudiantes y médicos, además van a constituir un respaldo para futuros trabajos de investigación. CONCLUSIÓN: Concluimos que la mayoría de pacientes pertenecen al sexo femenino, con una media de edad de 61 ±13.58 años, nivel de instrucción primario y estado civil casado, el porcentaje de no adherencia es de 65.8% y el principal factor social asociado a la no adherencia es el olvido

Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997-2010

OBJECTIVE: With improvements in cardiovascular disease (CVD) rates among people with diabetes, mortality rates may also be changing. However, these trends may be influenced by coding practices of CVD-related deaths on death certificates. We analyzed trends of mortality over 13 years in people with diabetes and quantified the potential misclassification of CVD mortality according to current coding methods. RESEARCH DESIGN AND METHODS: A total of 1,136,617 Australians with diabetes registered on the National Diabetes Services Scheme between 1997 and 2010 were linked to the National Death Index. Excess mortality relative to the Australian population was reported as standardized mortality ratios (SMRs). Potential misclassification of CVD mortality was determined by coding CVD according to underlying cause of death (COD) and then after consideration of both the underlying and other causes listed in part I of the death certificate. RESULTS: For type 1 diabetes, the SMR decreased in males from 4.20 in 1997 to 3.08 in 2010 (Ptrend < 0.001) and from 3.92 to 3.46 in females (Ptrend < 0.01). For type 2 diabetes, the SMR decreased in males from 1.40 to 1.21 (Ptrend < 0.001) and from 1.56 to 1.22 in females (Ptrend < 0.001). CVD deaths decreased from 35.6 to 31.2% and from 31.5 to 27.2% in males and females with type 1 diabetes, respectively (Ptrend < 0.001 for both sexes). For type 2 diabetes, CVD decreased from 44.5 to 29.2% in males and from 45.5 to 31.6% in females (Ptrend < 0.001 for both sexes). Using traditional coding methods, ∼38 and 26% of CVD deaths are underestimated in type 1 diabetes and type 2 diabetes, respectively. CONCLUSIONS: All-cause and CVD mortality has decreased in diabetes. However, the total CVD mortality burden is underestimated when only underlying COD is considered. This has important ramifications for understanding mortality patterns in diabetes.

Explaining psychological insulin resistance in adults with non-insulin-treated type 2 diabetes: the roles of diabetes distress and current medication concerns. Results from diabetes MILES-Australia.

AIMS: To investigate the contribution of general and diabetes-specific emotional wellbeing and beliefs about medicines in the prediction of insulin therapy appraisals in adults with non-insulin-treated type 2 diabetes. METHODS: The sample included Diabetes MILES-Australia cross-sectional survey participants whose primary diabetes treatment was oral hypoglycaemic agents (N=313; 49% women; mean±SD age: 57±9 years; diabetes duration: 7±6 years). They completed validated measures of beliefs about the 'harm' and 'overuse' of medications in general (BMQ General); 'concerns' about and 'necessity' of current diabetes medications (BMQ Specific); negative insulin therapy appraisals (ITAS); depression (PHQ-9); anxiety (GAD-7), and diabetes distress (DDS-17). Factors associated with ITAS Negative scores were examined using hierarchical multiple regressions. RESULTS: Twenty-two percent of the variance in ITAS Negative scores (52±10), was explained by: number of complications (β=-.15, p=.005), DDS-17 subscale 'emotional burden' (β=.23, p<.001), and 'concerns' about current diabetes treatment (β=.29, p<.001). General beliefs about medications and general emotional wellbeing did not contribute significantly to the model. CONCLUSIONS: Psychological insulin resistance may reflect broader distress about diabetes and concerns about its treatment but not general beliefs about medicines, depression or anxiety. Reducing diabetes distress and current treatment concerns may improve attitudes towards insulin as a potential therapeutic option.

The contribution of workplace characteristics to the risk of Type 2 Diabetes

Diabetes has a significant economic impact on individuals, families, health systems, and countries [1]. In 2010 it was estimated that the global health expenditure on diabetes was US376 billion (€292 billion), equating to 12% of health expenditure and US1330 (€1031) per person [2]. A separate estimate in 2010 reported that diabetes cost the US US174 billion (€135 billion), with US58 billion (€45 billion) in indirect costs equating to over US2000 (€1551) on average per person with diabetes [3]. The World Health Organization estimates that between 2005 and 2030 the proportion of deaths caused by diabetes will double and global health expenditures associated with diabetes are expected to reach US490 billion (€380 billion) [1,2]. In 2003, it was estimated that diabetes cost Australia AUS6 billion (US6 billion, €5 billion), with AUS21 million (US22 million, €17 million) in indirect costs such as lost workdays and lost productivity equating to approximately AUS35 (US35, €28) per person with diabetes [4].